Advertisement

Advertisement
Matthew Smeltzer, PhD, on International Lung Cancer Clinical Trials: The Impact of COVID-19

Matthew Smeltzer, PhD, on International Lung Cancer Clinical Trials: The Impact of COVID-19

DESTINY-Lung01: Fam-trastuzumab Deruxtecan-nxki in Previously Treated HER2-Mutant NSCLC

DESTINY-Lung01: Fam-trastuzumab Deruxtecan-nxki in Previously Treated <em>HER2</em>-Mutant NSCLC

In the phase II DESTINY-Lung01 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2021 and concurrently reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, and colleagues found that fam-trastuzumab deruxtecan-nxki produced durable responses in a high proportion of patients with previously treated HER2-mutant non–small cell lung cancer (NSCLC).

IMpower010 Study of Atezolizumab in Resectable NSCLC: Benefits Observed Regardless of Stage, Type of Prior Treatment

IMpower010 Study of Atezolizumab in Resectable NSCLC: Benefits Observed Regardless of Stage, Type of Prior Treatment

In an exploratory analysis of the pivotal phase III IMpower010 trial—which found that adjuvant atezolizumab significantly improved disease-free survival in resectable non–small cell lung cancer (NSCLC)—benefit was shown regardless of the type of surgery or the chemotherapy doublet received by the patient, according to findings reported by Nasser Altorki, MD, and colleagues at a Plenary Session of the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer.

POSEIDON Trial: Dual Checkpoint Blockade Plus Chemotherapy Improves Survival in First-Line Metastatic NSCLC

POSEIDON Trial: Dual Checkpoint Blockade Plus Chemotherapy Improves Survival in First-Line Metastatic NSCLC

Findings from the phase III POSEIDON trial showed significantly improved progression-free and overall survival in patients with metastatic NSCLC who received first-line durvalumab and tremelimumab plus chemotherapy vs chemotherapy alone. These findings were presented by Melissa L. Johnson, MD, and colleagues at the IASLC 2021 World Conference on Lung Cancer.

Atezolizumab Plus Chemotherapy in Patients With Advanced NSCLC and Brain Metastases

Atezolizumab Plus Chemotherapy in Patients With Advanced NSCLC and Brain Metastases

Patients with advanced non–small cell lung cancer (NSCLC) and brain metastases derived benefit from treatment with atezolizumab plus chemotherapy, according to findings from the multicenter phase II ATEZO-BRAIN/GECP 17/05 trial. The study was presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer by Ernest Nadal, MD, and colleagues.

Addition of Ramucirumab to Gemcitabine in Second-Line Treatment of Malignant Pleural Mesothelioma

In the Italian phase II RAMES trial reported in The Lancet Oncology, Pinto et al found that the addition of ramucirumab to gemcitabine improved overall survival in the second-line treatment of malignant pleural mesothelioma.

Advertisement


Advertisement